By Fineline Cube 
Merck & Co., Inc. (MSD; NYSE: MRK) announced that it has signed a collaboration agreement with InventisBio to jointly advance the clinical development of small‑molecule drugs in oncology. Leveraging the MSD R&D China Innovation and Collaboration Center (MCICC), the collaboration integrates InventisBio’s oncology insights and R&D execution capabilities to accelerate the clinical progress of relevant pipelines.
Deal Overview
| Item | Detail |
|---|---|
| Companies | Merck & Co., Inc. (MSD; NYSE: MRK) / InventisBio |
| Agreement Type | Collaboration agreement |
| Focus Area | Clinical development of small‑molecule drugs in oncology |
| Platform | MSD R&D China Innovation and Collaboration Center (MCICC) |
| Announcement Date | 11 Aug 2026 |
| Objective | Accelerate clinical progress of relevant oncology pipelines |
Scope of the Collaboration
- Joint Clinical Development: The two parties will jointly advance the clinical development of small‑molecule oncology candidates, combining Merck’s global development infrastructure with InventisBio’s local execution.
- MCICC‑Led Structure: The agreement is executed through MCICC, Merck’s dedicated China innovation hub, signalling a structured, repeatable model for external partnership in the market.
- Complementary Capabilities: The collaboration integrates InventisBio’s oncology insights and R&D execution capabilities into Merck’s pipeline acceleration strategy.
MCICC Track Record
| Metric | Since Inception (2024) |
|---|---|
| Established | 2024 |
| Focus | Early‑stage, high‑potential projects |
| Collaboration Agreements Signed | 4 with local companies in China |
| Companies Engaged | Over 600 domestic companies |
| In‑Depth Discussions | More than 100 companies |
- Early‑Stage Focus: Since it was officially established in 2024, MCICC has focused on early‑stage, high‑potential projects within China’s biotech ecosystem.
- Broad Funnel: The center has communicated and engaged with over 600 domestic companies and conducted in‑depth discussions with more than 100 of them, building a substantial deal‑sourcing pipeline.
Market Impact & Outlook
- China Sourcing Strategy: The deal reinforces Merck’s strategy of tapping China’s innovation ecosystem as a source of differentiated oncology assets, following the broader industry trend of multinational pharma licensing and co‑developing Chinese‑origin candidates.
- Oncology Pipeline Priority: Oncology remains Merck’s core growth engine; supplementing internal discovery with external small‑molecule candidates helps diversify its portfolio beyond biologics.
- Platform Maturation: With four collaboration agreements in roughly two years, MCICC is transitioning from a scouting office into an active deal‑making platform for Merck in Asia.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding clinical development plans and collaboration expectations. Actual results may differ due to risks including regulatory approvals, clinical outcomes, and definitive development agreements.-Fineline Info & Tech